Stock KITE PHARMA INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Kite Pharma Inc

Equities

US49803L1098

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Kite Pharma : Gilead Sciences Completes Acquisition of Kite Pharma, Inc.
BU
Kite Pharma : Gilead Sciences Completes Tender Offer for All Outstanding Shares of Kite Pharma, Inc.
BU
Kite Pharma : Gilead Sciences and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period
BU
Kite Pharma : Companies to Watch as Biotech Makes a Comeback in 2017
PR
Kite Pharma : Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
BU
Kite Pharma : Highlights Publication from the National Cancer Institute Demonstrating Responses in Patients with Metastatic Solid Tumors Treated with T Cell Receptor (TCR) Therapy Targeting MAGE A3
BU
Kite Pharma : Reports Second Quarter 2017 Financial Results
BU
Kite Pharma : Submits Investigational New Drug (IND) Application for -585, Anti-BCMA CAR-T Therapy Candidate for Multiple Myeloma
PU
Kite Pharma : Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD
PU
Kite Pharma : Doses First Patient in the Phase 2 Trial of Axicabtagene Ciloleucel in Indolent B-Cell Non-Hodgkin Lymphoma (ZUMA-5)
PU
Kite Pharma : to Report Second Quarter 2017 Financial Results on August 8, 2017
PU
Kite Pharma : Announces Initiation of Axicabtagene Ciloleucel CAR-T Clinical Program in the European Union
BU
Kite Pharma : Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD
BU
Kite Pharma : Doses First Patient in the Phase 2 Trial of Axicabtagene Ciloleucel in Indolent B-Cell Non-Hodgkin Lymphoma (ZUMA-5)
BU
Kite Pharma : to Present at August 2017 Investor Conference
BU
Kite Pharma : to Report Second Quarter 2017 Financial Results on August 8, 2017
BU
Kite Pharma : Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel
BU
Kite Pharma : Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute
BU
Novartis : FDA panel backs Novartis' pioneering new cancer gene therapy
RE
Kite Pharma : U.S. Patent Office to Confirm Kite's Seminal Eshhar CAR-T Patent
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Kite Pharma Inc